Literature DB >> 1034246

Anterior segment ischemia and sector iris atrophy: after strabismus surgery in a patient with chronic lymphocytic leukemia.

D S Jacobs, D W Vastine, M J Urist.   

Abstract

A 69-year-old woman with chronic lymphocytic leukemia developed segmental iris atrophy and iridocyclitis after routine surgery for exotropia. Both the clinical picture and fluorescein angiogram indicated anterior segment ischemia. It is postulated that this was related to hyperviscosity of the blood caused by a high white blood cell count (114,000/cu mm). The possibility of anterior segment ischemia should be kept in mind when contemplating strabismus or retinal detachment surgery in the presence of hematologic disorders likely to increase blood viscosity. In these cases a minimal amount of surgery should be done with proper supportive therapy. Strabismus surgery should be done in stages allowing for hemodynamic compensation between procedures.

Entities:  

Mesh:

Year:  1976        PMID: 1034246

Source DB:  PubMed          Journal:  Ophthalmic Surg        ISSN: 0022-023X


  4 in total

1.  The effect of rectus muscle recession, resection and plication on anterior segment circulation in humans.

Authors:  Erica Z Oltra; Stacy L Pineles; Joseph L Demer; Ann V Quan; Federico G Velez
Journal:  Br J Ophthalmol       Date:  2014-10-23       Impact factor: 4.638

2.  The ciliary vasculature and its perturbation with drugs and surgery.

Authors:  E M Van Buskirk
Journal:  Trans Am Ophthalmol Soc       Date:  1988

Review 3.  Lethal limb ischaemia in leukaemia. Case report and review of the literature.

Authors:  Cristina Belizna; Marc Antoine Pistorius; Bernard Planchon
Journal:  J Thromb Thrombolysis       Date:  2008-10-11       Impact factor: 2.300

Review 4.  [Unilateral combined strabismus surgery to correct esotropia : Video article on recession of the medial rectus muscle and plication of the lateral rectus muscle].

Authors:  Y Wenner; C Kuhli-Hattenbach; T Kohnen
Journal:  Ophthalmologe       Date:  2018-11       Impact factor: 1.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.